Next Article in Journal
Oxygenated Polyketides from Plakinastrella mamillaris as a New Chemotype of PXR Agonists
Next Article in Special Issue
pH-Dependent Solution Structure and Activity of a Reduced Form of the Host-Defense Peptide Myticin C (Myt C) from the Mussel Mytilus galloprovincialis
Previous Article in Journal
Nepheliosyne B, a New Polyacetylenic Acid from the New Caledonian Marine Sponge Niphates sp.
Previous Article in Special Issue
Conopeptides from Cape Verde Conus crotchii
Mar. Drugs 2013, 11(7), 2293-2313; doi:10.3390/md11072293
Review

Strategies for the Development of Conotoxins as New Therapeutic Leads

,
 and *
Received: 14 April 2013; in revised form: 27 May 2013 / Accepted: 6 June 2013 / Published: 28 June 2013
(This article belongs to the Special Issue Marine Peptides and Their Mimetics)
View Full-Text   |   Download PDF [659 KB, uploaded 28 June 2013]   |   Browse Figures
Abstract: Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins.
Keywords: peptide toxin; peptidomimetic; ion channel; pain; cone snail peptide toxin; peptidomimetic; ion channel; pain; cone snail
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Brady, R.M.; Baell, J.B.; Norton, R.S. Strategies for the Development of Conotoxins as New Therapeutic Leads. Mar. Drugs 2013, 11, 2293-2313.

AMA Style

Brady RM, Baell JB, Norton RS. Strategies for the Development of Conotoxins as New Therapeutic Leads. Marine Drugs. 2013; 11(7):2293-2313.

Chicago/Turabian Style

Brady, Ryan M.; Baell, Jonathan B.; Norton, Raymond S. 2013. "Strategies for the Development of Conotoxins as New Therapeutic Leads." Mar. Drugs 11, no. 7: 2293-2313.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert